EPG Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$104K Sell
811
-11
-1% -$1.37K 0.03% 205
2025
Q4
$100K Buy
822
+2
+0.2% +$229 0.03% 207
2025
Q3
$82.2K Buy
820
+11
+1% +$991 0.02% 211
2025
Q2
$67.1K Sell
809
-182
-18% -$14.5K 0.02% 213
2025
Q1
$80.4K Buy
991
+75
+8% +$6.7K 0.02% 263
2024
Q4
$82.5K Buy
916
+250
+38% +$24.2K 0.02% 267
2024
Q3
$65.8K Buy
+666
New +$65.4K 0.02% 284
2024
Q2
Sell
-666
Closed -$59.7K 304
2024
Q1
$63.2K Hold
666
0.02% 305
2023
Q4
$59.1K Buy
666
+206
+45% +$15.3K 0.02% 296
2023
Q3
$33.6K Buy
460
+278
+153% +$22.2K 0.01% 316
2023
Q2
$15.2K Buy
+182
New +$15.2K ﹤0.01% 340
2022
Q1
Sell
-261
Closed -$29K 438
2021
Q4
$29K Hold
261
0.01% 322
2021
Q3
$33K Buy
+261
New +$33.6K 0.01% 292
2020
Q2
Sell
-101
Closed -$8K 788
2020
Q1
$8K Hold
101
0.01% 526
2019
Q4
$10K Buy
+101
New +$8.74K 0.01% 432

Other funds holding XBI

EPG Wealth Management's XBI Position: Q1 2026 in Review

EPG Wealth Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 1.3% in Q1 2026, selling an estimated $1.37K and leaving 811 shares worth $104K. The position accounts for 0.03% of the portfolio, ranked #205.

EPG Wealth Management first reported a position in XBI in Q4 2019 and has held it in 15 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • EPG Wealth Management held 811 shares of State Street SPDR S&P Biotech ETF worth $104K as of Q1 2026.
  • EPG Wealth Management sold 11 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $1.37K.
  • State Street SPDR S&P Biotech ETF made up 0.03% of EPG Wealth Management's portfolio in Q1 2026, its #205 holding.
  • EPG Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2019 and has held it in 15 quarters since.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on EPG Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.